The Role of Cyclophilins and Cyclophilin Inhibitors in the Replication of HCV | Debio 025 | / | Publications

Menu Content/Inhalt

Home|Careers|Contact us

News

20.11.2008
Debiopharm and Aurigene sign licensing agreement for the development and commercialisation of Debio 0617, a novel inhibitor of an undisclosed oncology pathway
17.11.2008
Debiopharm and Pharmaleads sign license agreement for Debio 0827 or PL37 in treatment of chronic pain conditions

The Role of Cyclophilins and Cyclophilin Inhibitors in the Replication of HCV

Raf Crabbé

HEP DART 2007, Frontiers in Drug Development for Viral Hepatitis - Dec 2007 - Hawai/USA (Abstract)